Benefit of adjuvant chemotherapy after resection of stage II (T1-2N1M0) non-small cell lung cancer in elderly patients.

dc.contributor.author

Berry, Mark F

dc.contributor.author

Coleman, Brooke K

dc.contributor.author

Curtis, Lesley H

dc.contributor.author

Worni, Mathias

dc.contributor.author

D'Amico, Thomas A

dc.contributor.author

Akushevich, Igor

dc.coverage.spatial

United States

dc.date.accessioned

2017-06-05T19:48:07Z

dc.date.available

2017-06-05T19:48:07Z

dc.date.issued

2015-02

dc.description.abstract

BACKGROUND: We evaluated the use and efficacy of adjuvant chemotherapy after resection of T1-2N1M0 non-small cell lung cancer (NSCLC) in elderly patients. METHODS: Factors associated with the use of adjuvant chemotherapy in patients older than 65 years of age who underwent surgical resection of T1-2N1M0 NSCLC without induction chemotherapy or radiation in the Surveillance, Epidemiology, and End Results-Medicare database from 1992 to 2006 were assessed using a multivariable logistic regression model that included treatment, patient, tumor, and census tract characteristics. Overall survival (OS) was analyzed using the Kaplan-Meier approach and inverse probability weight-adjusted Cox proportional hazard models. RESULTS: Overall, 2,781 patients who underwent surgical resection as the initial treatment for T1-2N1M0 NSCLC and survived at least 31 days after surgery were identified, with adjuvant chemotherapy given to 784 patients (28.2 %). Factors that predicted adjuvant chemotherapy use were younger age and higher T status. The 5-year OS was significantly better for patients who received adjuvant chemotherapy compared with patients not given adjuvant chemotherapy: 35.8 % (95 % confidence interval [CI] 31.9-39.6) vs. 28.0 % (95 % CI 25.9-30.0) (p = 0.008). In the inverse probability weight-adjusted Cox proportional hazard regression model, adjuvant chemotherapy use predicted significantly improved survival (hazard ratio 0.84; 95 % CI 0.76-0.92; p = 0.0002). CONCLUSIONS: Adjuvant chemotherapy after resection of T1-2N1M0 NSCLC is associated with significantly improved survival in patients older than 65 years. These data can be used to provide elderly patients with realistic expectations of the potential benefits when considering adjuvant chemotherapy in this setting.

dc.identifier

https://www.ncbi.nlm.nih.gov/pubmed/25192680

dc.identifier.eissn

1534-4681

dc.identifier.uri

https://hdl.handle.net/10161/14822

dc.language

eng

dc.publisher

Springer Science and Business Media LLC

dc.relation.ispartof

Ann Surg Oncol

dc.relation.isversionof

10.1245/s10434-014-4056-0

dc.subject

Aged

dc.subject

Aged, 80 and over

dc.subject

Carcinoma, Non-Small-Cell Lung

dc.subject

Chemotherapy, Adjuvant

dc.subject

Female

dc.subject

Humans

dc.subject

Lung Neoplasms

dc.subject

Male

dc.subject

Neoplasm Staging

dc.subject

Pneumonectomy

dc.subject

Retrospective Studies

dc.subject

SEER Program

dc.subject

Survival Analysis

dc.title

Benefit of adjuvant chemotherapy after resection of stage II (T1-2N1M0) non-small cell lung cancer in elderly patients.

dc.type

Journal article

duke.contributor.orcid

Curtis, Lesley H|0000-0002-3286-9371

pubs.author-url

https://www.ncbi.nlm.nih.gov/pubmed/25192680

pubs.begin-page

642

pubs.end-page

648

pubs.issue

2

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Duke

pubs.organisational-group

Duke Cancer Institute

pubs.organisational-group

Duke Clinical Research Institute

pubs.organisational-group

Duke Population Research Institute

pubs.organisational-group

Faculty

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Institutes and Provost's Academic Units

pubs.organisational-group

Medicine

pubs.organisational-group

Medicine, General Internal Medicine

pubs.organisational-group

Physics

pubs.organisational-group

Sanford School of Public Policy

pubs.organisational-group

School of Medicine

pubs.organisational-group

Social Science Research Institute

pubs.organisational-group

Surgery

pubs.organisational-group

Surgery, Cardiovascular and Thoracic Surgery

pubs.organisational-group

Trinity College of Arts & Sciences

pubs.organisational-group

University Institutes and Centers

pubs.publication-status

Published

pubs.volume

22

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Benefit of Adjuvant Chemotherapy After Resection of Stage II (T1-2N1M0) Non-Small Cell Lung Cancer in Elderly Patients.pdf
Size:
245.04 KB
Format:
Adobe Portable Document Format